Savara Inc. $SVRA Shares Purchased by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. raised its holdings in Savara Inc. (NASDAQ:SVRA) by 1,088.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,842,350 shares of the company’s stock after buying an additional 1,687,310 shares during the period. Nan Fung Trinity HK Ltd. owned about 0.90% of Savara worth $9,507,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of SVRA. BlackRock Inc. acquired a new position in shares of Savara during the 2nd quarter worth about $76,966,000. Nantahala Capital Management LLC acquired a new stake in shares of Savara during the 2nd quarter worth about $42,977,150. Spruce Street Capital LP purchased a new stake in Savara during the second quarter worth approximately $21,267,868. ADAR1 Capital Management LLC purchased a new stake in Savara during the second quarter worth approximately $8,645,000. Finally, Algert Global LLC lifted its stake in Savara by 53.7% during the second quarter. Algert Global LLC now owns 1,329,259 shares of the company’s stock worth $8,188,000 after purchasing an additional 464,645 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SVRA has been the subject of a number of research analyst reports. JPMorgan Chase & Co. initiated coverage on Savara in a report on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 price target for the company. Wall Street Zen cut shares of Savara from a “hold” rating to a “sell” rating in a report on Sunday, October 4th. Royal Bank Of Canada set a $10.00 price objective on shares of Savara in a research report on Wednesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Thursday, October 15th. Finally, Citigroup restated a “market outperform” rating on shares of Savara in a report on Wednesday, October 7th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.29.

Savara Stock Performance

Shares of SVRA stock opened at $4.72 on Friday. The stock’s 50-day moving average is $4.95 and its two-hundred day moving average is $5.34. Savara Inc. has a 1 year low of $4.03 and a 1 year high of $7.01. The company has a quick ratio of 10.13, a current ratio of 8.55 and a debt-to-equity ratio of 0.28.

Savara (NASDAQ:SVRA) last posted its earnings results on Monday, November 9th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. As a group, sell-side analysts forecast that Savara Inc. will post -0.67 earnings per share for the current year.

About Savara

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.